ShareValue scores for GMT.WAR: Valuation 38, Quality 43, Growth 54, Health 50.

GMT.WAR
GPW

Genomtec S.A.

PLN 4.14(-3.39%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-6% to 11%
Valuation
38
Overvalued
Price vs Value
Quality
43
Moderate
Business Strength
Growth
54
Moderate
Revenue & Earnings
Health
50
Moderate
Financial Stability
Momentum
59
Neutral
Price Trend

Company Details

About

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026